Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES) - Wu, Lihteh; Martínez-Castellanos, María A.; Quiroz-Mercado, Hugo; Arevalo, J. Fernando; Berrocal, María H.; Farah, Michel E.; Maia, Mauricio; Roca, José A.; Rodriguez, Francisco J. (Graefe's archive for clinical and experimental ophthalmology, 2008)
Keywords: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Bevacizumab; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - physiopathology; Diabetic Retinopathy - drug therapy; Diabetic Retinopathy - physiopathology; Female; Humans; Injections; Macular Degeneration - drug therapy; Macular Degeneration - physiopathology; Macular Edema - drug therapy; Macular Edema - physiopathology; Male; Medicine; Medicine & Public Health; Middle Aged; Ophthalmology; Retinal Disorders; Retinal Vein Occlusion - drug therapy; Retinal Vein Occlusion - physiopathology; Retreatment; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity; Vitreous Body; Angiogenesis; Intravitreal bevacizumab; Choroidal neovascularization; Age-related macular degeneration; Proliferative diabetic retinopathy; Diabetic macular edema; Safety